Results 181 to 190 of about 38,575 (307)

Pancreatic Cancer—Advances in the Last 50 Years

open access: yes
World Journal of Surgery, EarlyView.
S. George Barreto   +5 more
wiley   +1 more source

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang   +5 more
wiley   +1 more source

Risk factors of delayed gastric emptying in patients after pancreaticoduodenectomy: a comprehensive systematic review and meta-analysis. [PDF]

open access: yesInt J Surg, 2023
Dai S   +15 more
europepmc   +1 more source

GLP‐1, GIP, and Glucagon Excursions During a Mixed Meal Tolerance Test in Young and Lean South Asians Versus Europids

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims South Asians exhibit an unfavourable metabolic phenotype characterized by visceral obesity, insulin resistance and dyslipidemia. While various hormones play a critical role in regulating postprandial energy metabolism, it remains unclear whether they respond differently to food intake.
Carlijn A. Hoekx   +8 more
wiley   +1 more source

Delayed Gastric Emptying Neither Contributes to Gastroesophageal Reflux nor Disease Severity in Patients With Respiratory Disease. [PDF]

open access: yesGastro Hep Adv
Bradley J   +7 more
europepmc   +1 more source

Five Advances in Benign Pancreatic Surgery in the Last 50 Years

open access: yes
World Journal of Surgery, EarlyView.
Stephan B. Dreyer, Rowan W. Parks
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Impact of feeding strategy after pancreatoduodenectomy on delayed gastric emptying and hospital stay: nationwide study. [PDF]

open access: yesBJS Open
Hendriks TE   +25 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy